Equillium, Inc.

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

Equillium announced new preclinical data from its EQ504 program will be presented in a poster at the 50th Anniversary La Jolla Immunology Conference, October 6-8, 2026. The data show EQ504, an aryl hydrocarbon receptor (AhR) modulator, coordinating effects across epithelial and immune compartments in an intestinal co-culture model, preserving barrier integrity while suppressing inflammatory cytokines. Management positions EQ504 as a potential oral, locally delivered therapy for ulcerative colitis; this is early-stage science with no clinical or financial milestones attached.

•26d ago

Equillium Announces Poster Presentations at the 7th International AHR Conference

Equillium announced two poster presentations of new preclinical data from its EQ504 program at the 7th International AHR Conference in Porto, Portugal, September 29 to October 2, 2026. The posters describe EQ504's effects on epithelial barrier repair and immune balance in translational models of ulcerative colitis, supporting selective AhR modulation as a therapeutic approach. This is standard scientific-conference visibility for an early-stage preclinical asset, with no new clinical or financial disclosures.

•1mo ago

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Equillium management will participate in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026, at 12:00pm EDT. Management will also be available to meet with registered investors, and the fireside chat will stream live via the Events & Presentations page under the investor relations section of equilliumbio.com. A replay of the webcast will remain available for approximately 45 days following the conference. The release contains no new clinical, financial, or regulatory information and is routine investor-relations scheduling.

•1mo ago

Equillium to Participate in Upcoming Investor Conferences

Equillium management will participate in two upcoming investor conferences in September 2026. The company is scheduled for a fireside chat and 1x1 meetings at the Cantor Global Healthcare Conference on September 9 at 9:45 AM EDT, followed by a company presentation and 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 11:00 AM EDT. A live webcast of the Cantor fireside chat will be available via the Equillium investor relations site, with a replay accessible for approximately 45 days after the conference.

•1mo ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium granted 145,000 nonstatutory stock options to a new employee as an induement award. The grant was approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the company’s 2024 Inducement Plan. The options have an exercise price of $3.08, matching the June 1 closing price, and vest over four years.

•4mo ago

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference

Equillium management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The session is scheduled for 4:55pm EDT, with management available to meet registered investors. No new clinical or financial data was disclosed in this announcement.

•5mo ago

Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

Equillium will host a virtual investor event on May 27, 2026, at 11:00 AM ET to present new preclinical insights. The presentation, led by Chief Scientific Officer Stephen Connelly, will focus on the mechanistic relationship between Aryl Hydrocarbon Receptor (AhR) activation and miR-124 induction in immune and epithelial cells. The company aims to resolve scientific controversy surrounding the AhR/miR-124 axis, which has implications for the rational development of its pipeline, including the investigational agent EQ504 for ulcerative colitis.

•5mo ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium granted inducement awards of 800,000 nonstatutory stock options to two new employees under its 2024 Inducement Plan. The options have an exercise price of $2.08 per share, equal to the closing price on the grant date, and vest over four years. These grants were approved by the Compensation Committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

•6mo ago